Have you heard that the FDA is reconsidering its approval of a gene therapy for Duchenne muscular dystrophy?
It appears that a senior bureaucrat at the FDA fast tracked the approval of the drug, despite some of their staff thinking that more study was needed.
Of course, if you read this in the news, you would not know it from the first couple of paragraphs, which were all about how the pharmaceutical company Sarepta's stock price tanked.
Seriously? Issues of possibly improper approval of a new drug, and the lede is f%$#ing stock price?
I weep for our media-industrial crisis.
0 comments :
Post a Comment